Springfusor for Administration of Magnesium Sulphate in Preeclampsia and Eclampsia

Preeclampsia and Eclampsia Clinical Trial

Official title:

Randomized Trial to Compare Magnesium Sulphate Administration for Preeclampsia and Eclampsia: Springfusor Versus Standard of Approach

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03549767
• Other study ID #: REC 2018-015
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 2018
• Est. completion date: August 2019

Study information

• Verified date: May 2018
• Source: Makerere University
• Contact: Sam Ononge, PhD
• Phone: +256772486301
• Email: ononge2006[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Magnesium Sulphate is the drug of choice for prevention and treatment of seizures in preeclampsia and eclampsia. It is administered parenterally by intravenous (IV) and or intramuscular (IM) routes. The IM regimen requires repeated painful injections which may be a barrier to optimal utilization whereby, there is frequent omission of some doses or increased interval between maintenance doses and low patient acceptability of magnesium. The study plans to assess the acceptability and safety of Springfusor device in the administration of magnesium sulphate in preeclampsia and eclampsia.

Description:

The IM regimen used in low resource settings, requires repeated painful injections which may be a barrier to optimal utilization whereby, there is frequent omission of some doses or increased interval between maintenance doses and low patient acceptability of magnesium. The study plans to assess the acceptability and safety of Springfusor device in the administration of magnesium sulphate in preeclampsia and eclampsia.

It is open label clinical randomized trail conducted at Mulago national referral and teaching hospital, where, 482 women diagnosed with preeclampsia and eclampsia will be randomized in blocks to either Springfusor device or standard of care for the administration of magnesium sulphate.

Women in the Springfusor group will have their loading dose (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 20 minutes) and maintenance therapy (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 4 hours. The 4 gm maintenance dose will be repeated every 4 hours for 24 hours) of Magnesium sulphate through an IV infusion administered using a Springfusor pump.

The control group will have Magnesium sulphate administered according to the Pritchard regimen (standard hospital practice). The Pritchard regimen involves administration of loading dose of 4 gm of 20% Magnesium sulphate IV over 15-20 minutes, immediately followed by 10 gm of 50% Magnesium sulphate IM (5gm on each buttock). The maintenance dose of 5 gm of 50% Magnesium sulphate IM every 4 hourly in alternate buttocks continued for 24 hours.

The primary outcome is the acceptability of administration of Magnesium sulphate using Springfusor assessed using a Likert scale. The other outcomes are discontinuation and complications in the two arms. Analysis will be intention to treat.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 241
• Est. completion date: August 2019
• Est. primary completion date: April 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 15 Years and older

Eligibility

Inclusion Criteria:

1. The study will include pregnant women with age of 15 years and above

2. Pregnancy of 20+ weeks of gestation or delivered within 24 hours,

3. Presenting with preeclampsia and eclampsia i.e. have a raised blood pressure (systolic of >140 mmHg and diastolic > 90mmHg), proteinuria >1+.

4. Presenting within the study period

5. Consent to participate in the study.

Exclusion Criteria:

1. Pregnant women or delivered within 24 hours who admitted with had received magnesium sulphate 24 hours prior to admission,

2. Has known allergy to magnesium sulphate and

3. Has elevated serum creatinine (>1.2 mg/dl). However the participants may be enrolled prior to the knowledge of serum creatinine, but withdrawn if the level is >1.2 mg/dl.

Related Conditions & MeSH terms

• Eclampsia
• Pre-Eclampsia
• Preeclampsia and Eclampsia

Intervention

Device:
• Springfusor
Springfusor for administration of magnesium sulphate

Procedure:
• Standard of care
Pritchard regimen. Magnesium sulphate is administered using hospital practice

Locations

Country	Name	City	State
Uganda	Mualgo Hospital	Kampala	Central

Sponsors (1)

Lead Sponsor	Collaborator
Makerere University

Country where clinical trial is conducted

Uganda, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acceptability of Springfusor	Acceptability of Springfusor for administration of magnesium sulphate will be assessed using a Likert scale ranging from one (very acceptable) to five (very unacceptable).	At 24 hours after loading dose
Secondary	Discontinuation	assessed as study participants who do not completed doses of magnesium sulphate	24 hour after the loading dose
Secondary	Level of pain	The study participants will be asked to assess the severity of pain during the administration of magnesium sulphate using Visual analogue scale 1-7.	At 24 hours after loading dose
Secondary	Safety of springfusor	Occurrence of respiratory depression eg rate <16/min	within 24 hours